Continuous Glucose Monitoring in Hospitalized Adults With Diabetic Ketoacidosis: A Prospective Open-Label Pilot Study
Authors' conclusion
Our study indicates that CGM technology is a reliable tool for hospital use during acute insulin treatment and after the resolution of DKA.
Study context
- Population
- Hospitalised adults with diabetic ketoacidosis (DKA) (T1D n = 24, T2D n = 28); age 49 ± 19 years, admission glucose 503 ± 239.4 mg/dL
- Participants
- 52 adults
- Exposure
- Real-time continuous glucose monitoring (CGM) vs capillary point-of-care (POC) and basic metabolic panel (BMP) glucose
- Outcome
- CGM accuracy vs POC: MARD, median ARD
- Follow-up
- During initial IV insulin period
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Mean absolute relative difference (MARD) vs POC, intravenous (IV) insulin period
17.4% ± 13.2%
Median absolute relative difference (ARD) vs POC, IV insulin period (IQR)
14.2%
6.4, 28
MARD vs POC, after DKA resolution
19.8% ± 18.7%
Median ARD vs POC, after DKA resolution (IQR)
14.3%
7, 26.2
Observational data: associations, not effects.
Further findings
Diabetes Technology Society (DTS) Error Grid: values in zones A+B
- During IV insulin treatment
- 100%
- After DKA resolution
- 95%
CGM accuracy vs BMP glucose: MARD, median ARD
- MARD vs BMP, IV insulin treatment
- 18.5% ± 19.1%
- Median ARD vs BMP, IV insulin treatment
- 12.2% (5.4, 23.8)
- MARD vs BMP, after DKA resolution
- 22.5% ± 24.7%
- Median ARD vs BMP, after DKA resolution
- 15.1% (6.6, 27.6)
Original publication
Continuous Glucose Monitoring in Hospitalized Adults With Diabetic Ketoacidosis: A Prospective Open-Label Pilot Study. J Diabetes Sci Technol. Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →